Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus

British Journal of Pharmacology

Volumn 163, Issue 5, 2011, Pages 937-947

  Dostalek, Miroslav ^a   Court, Michael H ^b   Yan, Bingfang ^a   Akhlaghi, Fatemeh ^a,c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

chlorzoxazone; cytochrome P450; diabetes mellitus; midazolam; P450; P450 2E1; P450 3A4; P450 3A5; testosterone

Indexed keywords

6 HYDROXYCHLORZOXAZONE; 6BETA HYDROXYTESTOSTERONE; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MESSENGER RNA; MIDAZOLAM; TESTOSTERONE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CATALYSIS; CELL FRACTIONATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HYDROXYLATION; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER LEVEL; LIVER METABOLISM; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS; FEMALE; GENOTYPE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

EID: 79958811096     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01270.x     Document Type: Article

References (43)

1. Anzenbacher P, Anzenbacherova E, (2001). Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58: 737-747. (Pubitemid 32553031)
2. Barnett CR, Flatt PR, Ioannides C, (1994). Modulation of the rat hepatic cytochrome P450 composition by long-term streptozotocin-induced insulin-dependent diabetes. J Biochem Toxicol 9: 63-69. (Pubitemid 2080566)
3. Donato MT, Guillen MI, Jover R, Castell JV, Gomez-Lechon MJ, (1997). Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes. J Pharmacol Exp Ther 281: 484-490. (Pubitemid 27203106)
4. Donato MT, Gomez-Lechon MJ, Jover R, Nakamura T, Castell JV, (1998). Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 284: 760-767. (Pubitemid 28086669)
5. Dostalek M, Macwan JS, Chitnis SD, Ionita IA, Akhlaghi F, (2010). Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1′-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878: 1629-1633.
6. Ernster L, Nordenbrand K, Orrenius S, Das ML, (1968). Microsomal lipid peroxidation. Hoppe Seylers Z Physiol Chem 349: 1604-1605.
7. Favreau LV, Schenkman JB, (1988). Composition changes in hepatic microsomal cytochrome P-450 during onset of streptozocin-induced diabetes and during insulin treatment. Diabetes 37: 577-584.
8. Gawronska-Szklarz B, Musial D, Drozdzik M, Paprota B, (2003). Metabolism of lidocaine by liver microsomes from streptozotocin-diabetic rats. Pol J Pharmacol 55: 251-254. (Pubitemid 36656762)
9. Guengerich FP, (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39: 1-17. (Pubitemid 29222549)
10. Guengerich FP, Bartleson C, (2001). Analysis and Characterization of Enzymes and Nucleic Acids. In:, Hayes A, (ed.). Principles and Methods of Toxicology, 5th edn. Taylor & Francis: Philadelphia, USA, pp. 1625-1687.
11. Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS, (1982). Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry 21: 6019-6030. (Pubitemid 13184201)
12. Haas S, Merkelbach-Bruse S, Justenhoven C, Brauch H, Fischer HP, (2009). Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver. Pathol Res Pract 205: 716-725.
13. He P, Court MH, Greenblatt DJ, Von Moltke LL, (2005). Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77: 373-387. (Pubitemid 40719266)
14. Ingelman-Sundberg M, (2004). Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369: 89-104. (Pubitemid 38161226)
15. Johansson I, Eliasson E, Ingelman-Sundberg M, (1991). Hormone controlled phosphorylation and degradation of CYP2B1 and CYP2E1 in isolated rat hepatocytes. Biochem Biophys Res Commun 174: 37-42.
16. Kotlyar M, Carson SW, (1999). Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37: 8-19. (Pubitemid 29043392)
17. Krishna DR, Shekar MS, (2005). Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences. Methods Find Exp Clin Pharmacol 27: 559-567. (Pubitemid 41727530)
18. Kudo T, Toda T, Ushiki T, Ohi K, Ikarashi N, Ochiai W, et al,. (2010). Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice. Xenobiotica 40: 282-290.
19. Lee AM, Yue J, Tyndale RF, (2006). In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment. Drug Metab Dispos 34: 1508-1515. (Pubitemid 44285392)
20. Lin JH, Lu AY, (2001). Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41: 535-567. (Pubitemid 32385898)
21. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues A, et al,. (2001). Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29 (Pt 1): 368-374. (Pubitemid 32275548)
22. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al,. (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62: 162-172. (Pubitemid 34680528)
23. Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P, (1998). Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 12: 553-558. (Pubitemid 29166500)
24. Marques M, Coelho E, Dos Santos N, Geleilete T, Lanchote VL, (2002). Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58: 607-614. (Pubitemid 35478187)
25. Moises EC, Duarte Lde B, Cavalli Rde C, Marques MP, Lanchote VL, Duarte G, et al,. (2008). Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. Eur J Clin Pharmacol 64: 1189-1196.
26. Morgan ET, (1997). Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29: 1129-1188. (Pubitemid 28133460)
27. Omura T, Sato R, (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378.
28. Patki KC, Von Moltke LL, Greenblatt DJ, (2003). In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 31: 938-944. (Pubitemid 36759065)
29. Pucci L, Chirulli V, Marini S, Lucchesi D, Penno G, Gervasi PG, et al,. (2005). Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. Pharmacol Res 51: 561-565.
30. Purdon MP, Lehman-McKeeman LD, (1997). Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. J Pharmacol Toxicol Methods 37: 67-73. (Pubitemid 27235157)
31. Raza H, Ahmed I, Lakhani MS, Sharma AK, Pallot D, Montague W, (1996). Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochem Pharmacol 52: 1639-1642. (Pubitemid 26375470)
32. Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, Okuda K, (1993). Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 46: 621-627. (Pubitemid 23262955)
33. Sidhu JS, Omiecinski CJ, (1995). cAMP-associated inhibition of phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocyte cultures. J Biol Chem 270: 12762-12773.
34. Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD, (2004). Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32: 359-363. (Pubitemid 38263895)
35. Thummel KE, Schenkman JB, (1990). Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 37: 119-129. (Pubitemid 20038459)
36. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR, (2000). CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68: 82-91. (Pubitemid 30609830)
37. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC, (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55: 77-85. (Pubitemid 36110842)
38. Wang T, Shankar K, Ronis MJ, Mehendale HM, (2007). Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit Rev Toxicol 37: 413-459. (Pubitemid 47035211)
39. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, et al,. (2002). Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24: 329-337. (Pubitemid 35420057)
40. Yang J, Shi D, Yang D, Song X, Yan B, (2007). Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol 72: 686-694. (Pubitemid 47347303)
41. Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, et al,. (2003). Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 9: 359-363.
42. Zaluzny L, Farrell GC, Murray M, (1990). Effect of genetic obesity and experimental diabetes on hepatic microsomal mixed function oxidase activities. J Gastroenterol Hepatol 5: 256-263. (Pubitemid 20375186)
43. Zhu W, Song L, Zhang H, Matoney L, LeCluyse E, Yan B, (2000). Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos 28: 186-191. (Pubitemid 30069003)